Durect Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 13

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $434M

Durect General Information

Description

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.

Contact Information

Website
www.durect.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 10240 Bubb Road
  • Cupertino, CA 95014-4166
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • 10240 Bubb Road
  • Cupertino, CA 95014-4166
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Durect Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Merger/Acquisition 11-Sep-2025 $434M Completed Generating Revenue
12. 2PO 20-Jul-2023 Completed Generating Revenue
11. PIPE 08-Feb-2023 Completed Generating Revenue
10. 2PO 07-Feb-2023 Completed Generating Revenue
9. 2PO 15-Apr-2016 Completed Generating Revenue
8. PIPE 01-Jul-2010 Completed Generating Revenue
7. PIPE 18-Sep-2009 Completed Generating Revenue
6. IPO 28-Sep-2000 Completed Generating Revenue
5. Later Stage VC (Series C) 28-Mar-2000 $25M $60.8M Completed Generating Revenue
4. Early Stage VC (Series B1) 01-Oct-1999 $699K $35.8M Completed Product Development
To view Durect’s complete valuation and funding history, request access »

Durect Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B1
Series B
Series A2 8,641,867 $0.000100 $0.05 $1.09 $1.09 1x $1.09 22.27%
Series A1 5,600,000 $0.000100 $0.05 $1 $1 1x $1 14.43%
To view Durect’s complete cap table history, request access »

Durect Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceuti
Drug Discovery
Cupertino, CA
13 As of 2025

Basel, Switzerland
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Durect Competitors (44)

One of Durect’s 44 competitors is Novartis, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland
Cipla Corporation Mumbai, India
Sun Pharmaceutical Industries Corporation Mumbai, India
Alkermes Formerly VC-backed Dublin, Ireland
Otsuka Holdings Corporation Tokyo, Japan
You’re viewing 5 of 44 competitors. Get the full list »

Durect Patents

Durect Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025101669-A1 Treatment of alcohol-associated hepatitis Inactive 07-Nov-2023
AU-2023411014-A1 25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and medical uses of same Pending 23-Dec-2022
EP-4637722-A1 25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and medical uses of same Pending 23-Dec-2022
WO-2024138203-A1 25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and medical uses of same Inactive 23-Dec-2022
AU-2022491085-A1 Salts including crystalline salts of 25-hydroxy-cholest-5-en-3-sulfate and methods for preparing same Pending 23-Dec-2022 C07J31/006
To view Durect’s complete patent history, request access »

Durect Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Durect Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Azimuth Opportunity Investment Bank Minority
Bain Capital Public Equity Hedge Fund Minority
CHL Medical Partners Venture Capital Minority
Premier Medical Partner Fund Venture Capital Minority
Venrock Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Durect Acquisitions (2)

Durect’s most recent deal was a Merger/Acquisition with Southern BioSystems for . The deal was made on 30-Apr-2001.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Southern BioSystems 30-Apr-2001 Merger/Acquisition Drug Delivery
ALZET 01-Jan-2000 Merger/Acquisition Therapeutic Devices
To view Durect’s complete acquisitions history, request access »

Durect ESG

Risk Overview

Risk Rating

Updated February, 28, 2026

40.27 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Pharmaceuticals

Subindustry

of 406

Rank

Percentile

To view Durect’s complete esg history, request access »

Durect FAQs

  • When was Durect founded?

    Durect was founded in 1998.

  • Where is Durect headquartered?

    Durect is headquartered in Cupertino, CA.

  • What is the size of Durect?

    Durect has 13 total employees.

  • What industry is Durect in?

    Durect’s primary industry is Drug Discovery.

  • Is Durect a private or public company?

    Durect is a Private company.

  • What is the current valuation of Durect?

    The current valuation of Durect is .

  • What is Durect’s current revenue?

    The current revenue for Durect is .

  • How much funding has Durect raised over time?

    Durect has raised $253M.

  • Who are Durect’s investors?

    Azimuth Opportunity, Bain Capital Public Equity, CHL Medical Partners, Premier Medical Partner Fund, and Venrock are 5 of 6 investors who have invested in Durect.

  • Who are Durect’s competitors?

    Novartis, Cipla, Sun Pharmaceutical Industries, Alkermes, and Otsuka Holdings are some of the 44 competitors of Durect.

  • When was Durect acquired?

    Durect was acquired on 11-Sep-2025.

  • Who acquired Durect?

    Durect was acquired by Bausch Health Companies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process